



Autoimmune encephalitis: a review of 
diagnosis and treatment
Encefalites autoimunes: uma revisão sobre diagnóstico e tratamento
Lívia Almeida Dutra1,2, Fabiano Abrantes1, Fabio Fieni Toso1, José Luiz Pedroso1, Orlando Graziani Povoas 
Barsottini1, Romana Hoftberger3
Autoimmune encephalitis (AIE) is considered one of the 
most common causes of noninfectious acute encephalitis. It is 
estimated that 20% of all encephalitis cases in northern Europe 
are immune-mediated1. The California Encephalitis Project 
found that anti-N-methyl-D-aspartate receptor (anti-NMDAR) 
encephalitis occurred in 47% of patients under 30 years of age2. 
Autoimmune encephalitis is typically an acute or subacute 
onset and that may become chronic later3. Suggested mech-
anisms that may trigger AIE include tumors (paraneoplastic), 
infections (parainfectious), or it may be cryptogenic4.
Autoimmune encephalitis has a wide variety of clinical 
manifestations including behavioral and psychiatric symp-
toms, autonomic disturbances, movement disorders and sei-
zures3,5. We reviewed common causes of AIE and discuss their 
pathophysiology, diagnostic approach and management.
Pathophysiology of autoimmune encephalitis: an 
overview
Autoimmune encephalitis presents an immune response 
against neuronal autoantigens with production of antibodies6. 
Anti-neuronal antibodies are classified into antibodies 
against cell surface antigens (CSAab), antibodies against syn-
aptic antigens (SyAab) and antibodies against intraneuronal 
antigens (INAab), also known as onconeural antibodies6,7.
The CSAab (i.e., anti-NMDAR antibodies) target mole-
cules involved in neurotransmission leading to neuronal dys-
function7. They may have agonistic or antagonistic effects on 
the receptors, block ion channel pores or disrupt the interac-
tion with neighboring molecules. They could also alter recep-
tor localization at the membrane or cause receptor internal-
ization, thus reducing cell surface expression of receptors7. 
Moreover, they could lead to complement deposition and 
activation of natural killer cells resulting in cell death7.
The SyAab are believed to contribute to alteration of neu-
rotransmitter release. In contrast, INAab (i.e., anti-Hu, anti-Yo, 
anti-Ma) are most likely not directly pathogenic and probably 
an epiphenomenon of T-cell-mediated immune response7.
The term AIE is used to describe a group of neurological dis-
orders with symptoms of limbic and extra-limbic dysfunction in 
association with CSAab or SyAab8. Patients may have antibodies 
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ABSTRACT
Autoimmune encephalitis (AIE) is one of the most common causes of noninfectious encephalitis. It can be triggered by tumors, infections, 
or it may be cryptogenic. The neurological manifestations can be either acute or subacute and usually develop within six weeks. There 
are a variety of clinical manifestations including behavioral and psychiatric symptoms, autonomic disturbances, movement disorders, and 
seizures. We reviewed common forms of AIE and discuss their diagnostic approach and treatment.
Keywords: encephalitis; antibodies, neoplasm; status epilepticus; anti-N-Methyl-D-Aspartate receptor encephalitis; immunoglobulin; rituximab.
RESUMO
As encefalites autoimunes (EAI) são a principal causa de encefalite não-infecciosa. As manifestações neurológicas são variadas, incluindo 
alterações comportamentais ou psiquiátricas, disautonomia, transtornos do movimento e epilepsia. Habitualmente a instalação dos 
sintomas ocorre em até 6 semanas, de forma aguda ou subaguda. As EAI podem ser desencadeadas por tumores, quadros infecciosos virais 
ou ainda apresentar etiologia criptogênica. Este artigo revisa as principais EAI, estratégias de diagnóstico e tratamento.
Palavras-chave: encefalites; anticorpos antineoplásicos; status epiléptico; encefalite antirreceptor de N-Metil-D-Aspartato; imunoglobulinas; 
rituximab.
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of more than one type, and CSAab and SyAab may be present 
together with anti-INAab, especially in paraneoplastic AIE.
Patients with AIE associated with CSAab have a more 
favorable prognosis. In contrast, those with AIE associ-
ated with INAab often show limited response to immuno-
therapy and their symptoms are mostly irreversible due to 
T-cell-mediated neuronal damage6,7.
Clinical manifestations
Patients with AIE may present with a variety of move-
ment disorders such as ataxia, dystonia, myoclonus, and 
orofacial dyskinesia. Seizures are the most common symp-
tom and different types of seizures may be seen, including 
refractory status epilepticus9. Autonomic disturbances are 
also frequently reported such as sudoresis, hypertension, 
tachycardia and hypoventilation. Some patients may show 
involvement of the myenteric plexus and develop gastroin-
testinal manifestations (diarrhea, gastroparesis, and consti-
pation). Sleep disturbances such as agrypnia excitata, insom-
nia, abnormal sleep movements and behaviors, sleep apnea, 
and hypersomnia are also found10. Some of these findings are 
suggestive of a certain type of encephalitis and may indicate 
a specific underlying antibody and tumor (Figure 1).
Table 1 summarizes the diagnostic criteria for limbic 
encephalitis. These include working memory deficits, mood 
changes, and often seizures within three months from onset. 
Many patients with AIE present with a broader spectrum of 
neurological symptoms. For improving the recognition of 
immune-mediated cases, diagnostic criteria for suspected 
AIE were recently established including criteria for seronega-
tive AIE (Table 2). Definite soropositive AIE requires typical 
clinical picture and positive anti-neuronal antibodies
Anti-NMDAR encephalitis
Anti-N-methyl-D-aspartate  receptor encephalitis is 
one of the most common causes of AIE and was originally 
described in 2007 in a cohort of 12 patients, 11 of them with 
ovarian teratomas11. This condition predominantly affects 
children and young female patients3. Underlying malignan-
cies are found mainly in patients between the age of 12–45 
years; most of them are ovarian teratomas (94%), followed by 
extraovarian teratomas (2%), and other tumors (4%). Herpes 
simplex virus-1 encephalitis appears to be a trigger for anti-
NMDAR encephalitis; most postherpetic AIE cases are now 
believed to be anti-NMDAR encephalitis.
Approximately 70% of patients present with prodromal 
symptoms such as fever, headache, nausea, vomiting, diar-
rhea, and flu-like symptoms, two weeks before the onset of 
neurological manifestations. Behavioral complaints, psy-
chosis, delusions, hallucinations and paranoia, accompa-
nied with memory deficits and language disturbance, are 
frequently found at an early stage3,12. The most common 
movement disorders are orofacial dyskinesias, choreoatheth-
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mutism, followed by an altered level of consciousness and 
autonomic instability. An important differential diagnosis 
of anti-NMDAR encephalitis is neuroleptic malignant syn-
drome, because many patients are initially treated with neu-
roleptics for behavioral symptoms3,13. Table 3 summarizes the 
diagnostic criteria for anti-NMDAR encephalitis.
Seizures are seen in 16% of female and 34% of male 
patients; they can be focal seizures or patients may present 
with status epilepticus. Extreme delta brush is a specific elec-
troencephalogram (EEG) pattern found in 30% of patients with 
anti-NMDAR encephalitis14. Children more frequently present 
with behavioral symptoms and movement disorders, whereas 
adults present with psychiatric symptoms and seizures.
Brain magnetic resonance imaging (MRI) is abnormal in 
35% of patients at disease onset, but it may show late abnor-
malities in 50%, mainly nonspecific hyperintense lesions in 
the grey and white matter. Rare cases show lesions suggestive 
of demyelination and overlap with demyelinating syndromes 
such as neuromyelitis optica spectrum disorders (NMOSD) 
associated with anti-aquaporin-4 antibodies or demyelinat-




isoxazolepropionic acid receptor (anti-AMPAR) encephali-
tis characteristically present with seizures, memory impair-
ment and psychosis. Some may develop sleep disturbances 
and movement disorders. Anti-AMPAR encephalitis is para-
neoplastic in etiology in 64% of cases, mostly associated with 
thymoma, ovarian teratoma and lung and breast cancer. 
Brain MRI shows T2 and FLAIR hyperintensities, particularly 
in the medial temporal lobe. Subcortical and cortical lesions, 
which are sometimes suggestive of demyelination, may also 
be found. Cerebrospinal fluid (CSF) examination may show 
pleocytosis and oligoclonal bands15.
Anti-GABA-AR encephalitis
Anti-gamma-aminobutyric acid A receptor (anti-GABA-AR) 
encephalitis was first reported in 2014 in six patients (two 
male children, one female teenager and three male adults)16. 
They developed a rapidly progressive encephalopathy with 
early behavioral or cognitive changes that evolved with refrac-
tory seizures and multifocal lesions as seen on brain MRI16. 
In most of these patients, CSF analysis showed lymphocytic 
Table 2. Diagnostic criteria for autoimmune encephalitis.
Diagnostic criteria for possible autoimmune encephalitis (all three of the following criteria met):
1 – Subacute onset (rapid progression of less than three months) of working memory deficits (short-term memory loss), altered mental 
status (decreased level of consciousness, lethargy or personality changes), or psychiatric symptoms
2 – At least one of the following:
New focal CNS findings
Seizures not explained by previously-known seizure disorder
CSF pleocytosis
MRI suggestive of encephalitis
3 – Reasonable exclusion of alternative causes
Criteria for autoantibody-negative but probable autoimmune encephalitis (all four criteria met):
1 - Subacute onset (rapid progression of less than three months) of working memory deficits (short-term memory loss), altered mental 
status (decreased level of consciousness, lethargy or personality changes), or psychiatric symptoms
2 – Exclusion of well-defined syndromes of autoimmune encephalitis (typical limbic encephalitis, Bickerstaff, brainstem encephalitis, 
acute disseminated encephalomyelitis)
3 – Absence of well-characterized autoantibodies in serum and CSF, and at least two of the following criteria:
MRI abnormalities suggestive of autoimmune encephalitis
CSF pleocytosis, oligoclonal bands or elevated CSF IgG index, or both
Brain biopsy showing inflammatory infiltrates and excluding other disorders 
4 – Reasonable exclusion of alternative causes
CSF: cerebrospinal fluid; CNS: central nervous system.
Table 1. Diagnostic criteria for definite autoimmune limbic encephalitis.
Diagnosis can be made when all four of the following criteria have been met:
1 – Subacute onset (rapid progression of less than three months) of working memory deficits, seizures, or psychiatric symptoms 
suggesting involvement of the limbic system
2 – Bilateral brain abnormalities on MRI T2-weighted FLAIR sequence restricted to the medial temporal lobes
3 – At least one of the following: 
EEG with epileptic or slow-wave activity involving the temporal lobes
CSF pleocytosis
4 – Reasonable exclusion of alternative causes
MRI: magnetic resonance imaging; EEG: electroencephalogram; CSF: cerebrospinal fluid.
44 Arq Neuropsiquiatr 2018;76(1):41-49
pleocytosis with or without oligoclonal bands. A recent study 
identified an underlying neoplasia in 27% of these patients, 
mostly thymomas17. Similar to that seen in patients with anti-
gamma-aminobutyric acid B receptor (GABA-BR) and anti-
AMPAR antibodies, they may also present with coexisting 
autoimmune disorders such as thyroiditis or myasthenia18.
Anti-GABA-BR encephalitis
Anti-GABA-BR encephalitis is characterized by cognitive 
symptoms with severe seizures or status epilepticus19. Other 
presentations include ataxia and opsoclonus-myoclonus. 
In a small series of 20 patients with anti-GABA-BR, about 
50% were found to have small-cell lung cancer20. Males and 
females appear to be equally affected. The long-term progno-
sis in anti-GABA-BR encephalitis is determined by the pres-
ence of an underlying malignancy21.
Anti-LGI1 and anti-CASPR2 encephalitis (formerly 
known as anti-VGKC-associated encephalitis)
The first reports of anti-voltage-gated potassium chan-
nel-complex antibodies (anti-VGKC) date back to 2001 and 
described patients with neuromyotonia, Morvan’s syndrome 
and limbic encephalitis22. Other rare phenotypes included 
epilepsy and painful polyneuropathy23. Anti-VGKC antibod-
ies, in fact, later turned out to be directed against proteins 
that form a complex with VGKC called leucine-rich glioma-
inactivated 1 (LGI1 and contactin-associated protein-like 2 
(CASPR-2)24,25. Each of these antibodies presents with spe-
cific clinical symptoms.
The LGI1 is a secreted synaptic protein that interacts 
with transmembrane proteins ADAM22 and ADAM23 
to form a trans-synaptic complex involving potassium 
channels and AMPAR. Genetic disruption of LGI1 pro-
tein in humans causes autosomal dominant lateral tem-
poral lobe epilepsy26. The clinical spectrum of anti-LGI1 
encephalitis usually comprises limbic encephalitis, 
hyponatremia and seizures. Half of the patients develop 
faciobrachial dystonic seizures, which are characterized 
by brief unilateral contractions of the arm (often evolv-
ing into the ipsilateral face or leg) that are shorter than 
three seconds and occur several times a day. Two-thirds 
of patients present with brain MRI hyperintensities in 
the medial temporal lobe (Figure 2). Paraneoplastic 
anti-LGI1 encephalitis is uncommon; however, patients 
should be screened for lung cancer27. Relapses may occur 
in up to 20% of patients28.
Table 3. Diagnostic criteria for anti-NMDA receptor encephalitis.
Probable anti-NMDA receptor encephalitis
Diagnosis require all three of the following criteria
1 – Less than three months of at least four of the six following major group of symptoms: 
Abnormal (psychiatric) behavior or cognitive dysfunction
Speech dysfunction (pressured speech, verbal reduction, mutism)
Seizures
Movement disorder, dyskinesias, or rigidity/abnormal postures
Decreased level of consciousness
Autonomic dysfunction or central hypoventilation
2 – At least one of the following laboratory study results:
Abnormal EEG (focal or diffuse slow or disorganized activity, epileptic activity, or extreme delta brush)
CSF with pleocytosis or oligoclonal bands
3 – Reasonable exclusion of other disorders
Diagnosis can also be made in the presence of three of the above groups of symptoms accompanied by a systemic teratoma
Definite anti-NMDA receptor encephalitis
Diagnosis can be made in the presence of one or more of the six major groups of symptoms and IgG anti-GluN1 antibodies, after 
reasonable exclusion of other disorders 
EEG: electroencephalogram; CSF: cerebrospinal fluid.
Figure 2. FLAIR sequence, brain MRI. Hippocampal 
hyperintensities in anti-LG1 encephalitis.
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The CASPR-2 is a juxtaparanodal adhesion molecule 
that interacts with contactin 2 and the cytoskeleton, and 
is involved in clustering of potassium channels in myelin-
ated axons28. Anti-CASPR2 antibodies are associated with 
peripheral nerve hyperexcitability (myokymia, fasciculations, 
cramps) and encephalitis. Other symptoms include dysauto-
nomia and insomnia (agrypnia excitata). Nearly one-third 
of patients develop Morvan’s syndrome, a complex disorder 
affecting the peripheral and central nervous system that is 
characterized by distal movement disorders of the upper 
limbs, peripheral nerve hyperexcitability, dysautonomia, 
pain, and encephalitis24. Most individuals affected are male 
and one-third of them present with paraneoplastic mani-
festations, usually associated with thymoma, lung cancer or 
endometrial carcinoma27,26.
The clinical relevance of anti-VGKC antibodies against 
unknown target antigens is unclear. About half of patients 
with anti-VGKC encephalitis do not present antibodies 
against LGI1 or CASPR-2. These specific groups of patients 
develop a wide variety of clinical syndromes raising the ques-
tion whether anti-VGKC antibodies are truly a marker of dis-
ease in these patients25. Anti-VGKC antibodies have been 
described, for example, in patients with Creutzfeldt-Jakob 
disease, suggesting that these antibodies might not be patho-
genic. Anti-VGKC titers with negative anti-LGI1 and anti-
CASPR-2 antibodies are usually low (< 0.3 pM)—although 
there is no clear cutoff value to differentiate between patients 
with and without AIE—thus it is not recommended to use 
them as evidence of immune-mediated pathogenesis22,29.
Anti-GAD encephalitis
Glutamic acid decarboxylase (GAD) is an enzyme that 
catalyzes the conversion of glutamic acid to the neurotrans-
mitter GABA. Anti-GAD antibodies have been associated 
with other autoimmune disorders such as insulin-dependent 
diabetes mellitus. The main neurological syndromes asso-
ciated with anti-GAD antibodies include stiff-person syn-
drome, cerebellar ataxia, epilepsy and limbic encephalitis30.
Stiff-person syndrome is a neurological disorder fre-
quently associated with anti-GAD antibodies characterized 
by muscle stiffness resulting from co-contractions of agonist 
and antagonist muscles and painful spasms31. Another clas-
sic finding in this syndrome is the patient’s pronounced star-
tle responses.
Ataxia associated with anti-GAD antibodies is usually 
slowly progressive and evolves over months or years. Abnormal 
ocular movements with spontaneous downbeat nystagmus 
have also been described30. Nearly 7% of patients with anti-
GAD antibodies present with temporal lobe epilepsy or status 
epilepticus, and 5% develop limbic encephalitis32,33.
Anti-GAD antibodies are rarely of paraneoplastic ori-
gin. Patients with stiff-person syndrome, cerebellar ataxia or 
other neurological syndromes typically associated with anti-
GAD antibodies do not need to be aggressively or repeatedly 
screened for cancer. However, the presence of anti-GAD anti-
bodies in patients with  limbic encephalitis or other classic 
paraneoplastic syndromes (paraneoplastic cerebellar degen-
eration, opsoclonus-myoclonus syndrome or paraneoplastic 
encephalomyelitis) is associated with a 10-fold increase in the 
risk of cancer and tumor screening is thus recommended34.
Anti-GlyR encephalitis
Glycine receptors (GlyR) are chloride channels that facil-
itate inhibitory neurotransmission in the brain and spinal 
cord35. Anti-GlyR antibodies were first described in patients 
with progressive encephalomyelitis with rigidity and myoc-
lonus and later in patients with stiff-person syndrome31,35,36. 
Recently, anti-GlyR antibodies have also been reported in 
patients with cerebellar ataxia and anti-GAD antibodies and 
patients with demyelinating diseases including optic neuritis 
and multiple sclerosis, but their clinical significance remains 
unclear37,38. Anti-GlyR antibodies are usually not associated 
with tumors, although there have been reports of patients 
with underlying thymoma, small-cell lung cancer, breast can-
cer and chronic lymphocytic leukemia.
Anti-DPPX encephalitis
Dipeptidyl peptidase-like protein 6 (DPPX) is a subunit 
of Kv4.2 potassium channels expressed in the hippocampus, 
cerebellum, striatum, and myenteric plexus. Patients with 
anti-DPPX antibodies show neuropsychiatric symptoms 
(agitation and confusion), myoclonus, tremor, startle reflex, 
seizures, stiff-person syndrome and prodromal diarrhea of 
unknown etiology. In addition, they may have symptoms of 
dysautonomia including arrhythmias, thermodysregulation, 
diaphoresis, urinary symptoms and sleep disorders39,40.
The CSF analysis usually shows pleocytosis and 
increased protein concentrations. Functional tests in the 
serum of a DPPX-positive patient demonstrated increased 
excitability of enteric neurons and downregulation of DPPX 
and Kv4.2 from hippocampal neuron membranes, which is 
suggestive of the pathogenic effects of anti-DPPX antibod-
ies in anti-DPPX encephalitis39.
Encephalopathy associated with anti-IgLON5 
antibodies
The IgLON family member 5 (IgLON5) is a neuronal 
cell adhesion molecule of the immunoglobulin superfam-
ily. Patients with anti-IgLON5 antibodies present with a 
unique non-REM (rapid eye movement) and REM parasom-
nia with obstructive sleep apnea, stridor, episodic central 
hypoventilation, dementia, gait instability, chorea, dysar-
thria, dysphagia, dysautonomia and supranuclear gaze palsy 
resembling that seen in classic tauopathy5,40. All published 
cases reported the presence of the alleles HLA-DQB1*0501 
and HLA-DRB1*1001 suggesting genetic susceptibility to 
this disease. Neuropathological postmortem studies have 
shown a novel tauopathy with extensive neuronal deposits of 
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hyperphosphorylated tau mainly involving the tegmentum of 
the brainstem and hypothalamus41. This novel encephalopa-
thy provides an intriguing link between neurodegeneration 
and cell-surface autoimmunity. A recent study has shown 
that anti-IgLON5 antibodies recognize Ig-like domain 2 as an 
immunogenic region and causes irreversible internalization 
of IgLON5 from the neuronal membrane. These findings sup-
port a potential pathogenic role of anti-IgLON5 antibodies in 
the associated encephalopathy42.
Anti-mGluR1 and anti-mGluR5 encephalitis
Metabotropic glutamate receptor 1 (mGluR1) and 
metabotropic glutamate receptor 5 (mGluR5) are both 
G-protein-coupled receptors that share an 85% amino acid 
sequence homology. Both receptors are involved in modulat-
ing synaptic functions including long-term depression. While 
mGluR1 facilitates long-term depression at parallel fiber 
Purkinje cell synapses, which are critical for cerebellar motor 
learning, mGluR5 is more relevant for long-term depression 
in the hippocampus.
All patients with anti-mGluR1 antibodies develop cere-
bellar ataxia of subacute onset, and some may present with 
additional symptoms such as paranoia, dysgeusia, diplopia 
and cognitive deficits. Common tumors found to be associ-
ated with anti-mGluR1 antibodies are hematologic malig-
nancies and prostate adenocarcinoma43. Response to immu-
notherapy is variable.
Patients with anti-mGluR5-abs present with a form of 
encephalitis named “Ophelia syndrome”, a clinical syn-
drome that includes memory loss and psychosis in associa-
tion with Hodgkin’s lymphoma44. The outcome of reported 
cases is generally good after treatment of the lymphoma 
and immunotherapy44.
Considerations on specific diagnostic methods for AIE
Four different techniques are used to detect antibodies 
against cell surface antigens: cell-based assay (CBA) with 
HEK293 cells; tissue-based assay (TBA) on brain tissue of 
rodents using indirect immunohistochemistry or indirect 
immunofluorescence, and culture of dissociated hippocam-
pal neurons from rats.
Cell-based assays are highly sensitive and robust signals 
are diagnostic of specific antigens45. The TBA provides an 
excellent screening approach as it can detect most currently-
known antibodies and reveal new antibodies. Staining of live 
neuronal cell cultures are performed mainly in research labo-
ratories and can be useful when TBAs and CBAs show con-
flicting results. It confirms that antibodies directed against 
neuronal surface antigens are present (Figure 3).
Testing for surface receptor antibodies should always 
be performed in both serum and CSF of the patients. This 
has several reasons: (1) in some specific syndromes (e.g. 
anti-NMDAR encephalitis) anti-neuronal antibodies may 
be found only in CSF (in a recent study 13% of anti-NMDAR 
encephalitis patients did not have detectable anti-NMDAR 
antibodies in serum46) while other antibodies (e.g. LGI1) 
may, in rare instances, be detectable only in serum. (2) Some 
patients may have a different antibody spectrum in serum 
and CSF, for example, some patients may have anti-NMDAR 
encephalitis in serum and CSF and, in addition, GABA-AR 
antibodies only in serum. In these cases, the antibody present 
in the CSF determines the clinical phenotype. (3) Antibody-
titers in CSF correlate better with the clinical presentation 
than serum titers, and (4) serum testing harbors the risk of 
background reactivity that gives rise to false positive results. 
Recently, serum testing with CBA identified anti-NMDAR 
antibodies mainly of the IgA and IgM subclass in schizophre-
nia, Creutzfeldt-Jakob disease, depression, Parkinson’s dis-
ease, and healthy individuals46. However, presence of these 
antibodies could not be shown in CSF and, therefore, the 
clinical significance of serum IgA and IgM anti-NMDAR anti-
bodies remains to be clarified.
There are diagnostic challenges to testing for AIE in Brazil 
as commercial CBA and TBA kits are not approved for use by 
national regulatory authorities. Partner or research laborato-
ries overseas perform most testing and some of these labo-
ratories perform CBAs only. We currently recommend that 
samples from patients with clinical manifestations sugges-
tive of AIE who tested negative by CBA should be referred 
to research laboratories that use other assessment methods.
Negative test results do not rule out immune-mediated 
disorders and nonspecific background signals may cause false 
positive test results. Steroid use may also interfere with the 
diagnostic test. Hence, test results should be interpreted with 
caution and put into the context of the clinical presentation. 
Figure 3. Techniques for the detection of anti-neuronal 
antibodies. Indirect immunohistochemistry on rat brain tissue 
with a serum of a patient with anti-NMDAR encephalitis 
shows strong labeling of hippocampal neurons (A) whereas a 
serum of a healthy individual is negative (B). In the cell-based 
assay, antibodies are identified on HEK293 cells transfected 
with related antigens. (C) red: CSF from a patient with AMPAR 
antibodies, green: commercial antibody against the GluA1/2 
subunits of AMPARs). (D) Live hippocampal neuron culture; 
strong dot-like labeling of the neuronal membrane indicates 
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Because antibodies may remain positive despite clinical fea-
tures, clinicians should focus on patient treatment rather 
than antibody titers.
Differential diagnosis
Differential diagnosis in anti-neuronal AIE includes 
Hashimoto’s encephalopathy and other steroid-responsive 
encephalopathies, acute disseminated encephalomyeli-
tis, neuromyelitis optica spectrum disorders, central ner-
vous system vasculitis, neuropsychiatric lupus, angiocentric 
lymphoma, Rasmussen’s encephalitis and febrile infection-
related epilepsy syndrome. It is important to rule out HIV 
infection, syphilis, Creutzfeldt-Jakob disease, as well as 
human herpes virus-6-associated encephalitis in immuno-
compromised patients1,3,8,33.
Viral infections are known triggers for AIE3,4. It is believed 
that virus-mediated cerebral tissue damage may lead to anti-
gen exposition that triggers the development of anti-neuro-
nal antibodies. Herpes viruses may trigger autoimmunity to 
NMDAR, dopamine D2 receptor, GABA-AR and other synap-
tic proteins that have are not yet been characterized.
Tumor investigation
All patients with AIE should be screened for tumors at 
disease onset. The nature of the antibody, and to a lesser 
extent the clinical syndrome, determines the risk and type 
of an underlying malignancy47. Due to the low frequency of 
tumor association in patients with anti-LGI1 and anti-GAD 
antibodies, patient screening should be considered at disease 
onset, with no need for periodic screenings8. Tumor treat-
ment is essential for neurological improvement25.
If initial tumor screening is negative but the patient 
has antibodies that are typically paraneoplastic (e.g. anti-
NMDAR in young adult women, anti-CASPR2, anti-AMPAR 
and anti-GABA-BR), screening should be repeated after three 
to six months, followed by screenings every six months for 
four years48.
Computed tomography (CT) of the chest should be per-
formed; if negative, fluorodeoxyglucose positron emission 
tomography (FDG-PET) is indicated as it increases cancer 
detection by 20%49. Mammograms followed by MRI are used 
for breast cancer screening. For the pelvic region and testes, 
ultrasound is the investigation of first choice followed by pel-
vic CT47. It is important to note that ovarian teratomas are 
not seen in FDG-PET scans.
Treatment and prognosis
Various treatment approaches including corticosteroids, 
intravenous immunoglobulin, plasma exchange, rituximab 
and cyclophosphamide are currently used13. Data on treat-
ment response and prognosis are mostly available for anti-
NMDAR encephalitis50.
Evidence suggests that early immunotherapy improves 
outcome3, thus treatment for AIE should not be delayed. 
Patients should receive either methylprednisolone 1 g IV for 
3–5 days and intravenous immunoglobulin (0.4 g/kg/day for 
five days) or methylprednisolone and plasmapheresis. We 
favor the use of plasmapheresis in patients with refractory 
seizures and severe dysautonomia, although there is no com-
pelling evidence of superiority of any approach. If an associ-
ated tumor is detected, oncologic management (chemother-
apy or tumor resection) is important for improvement.
Autoimmune encephalitis patients who fail to improve 
after 10–14 days should receive second-line therapies such as 
rituximab or cyclophosphamide, or both3,13. Specialized cen-
ters usually prescribe rituximab (375 mg/m2) weekly for four 
weeks and cyclophosphamide (750 mg/m2) for six months in 
patients older than 16 years. Younger patients should receive 
rituximab alone3.
Better prognosis has been associated with early treat-
ment, no requirement for intensive care admission and non-
paraneoplastic AIE20. The treatment response and relapse 
rate vary among patients with AIE. Half of the patients with 
anti-NMDAR encephalitis fail initial immunotherapy and 
may require second-line treatment options, with relapses 
occurring in 12%. Relapses may occur in 31% of patients with 
anti-LGI1 encephalitis and 10% of those with anti-CASPR2 
encephalitis, sometimes years after the first episode. About 
33% of the patients with anti-LGI1 encephalitis are left dis-
abled, mostly due to memory problems.
FINAL REMARKS
Autoimmune encephalitis may present with a wide variety 
of symptoms of either acute or subacute onset. The diagnosis 
should not rely solely on antibody testing as patients with AIE 
may be seronegative. Clinicians must be aware of the differ-
ent laboratory assessment methods available as well as proper 
interpretation of results. Clinical presentation and physical 
examination are of extreme importance in AIE. Patients ben-
efit from early aggressive treatment and relapses may occur.
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